ITRM (Iterum Therapeutics) Short-Term Debt to Capital

Iterum Therapeutics plc (ITRM) faces threats from regulatory application rejections, a high cash burn rate, and pressure from low-cost generics. Meanwhile, management is successfully adjusting the market launch plan for its lead drug while maintaining shareholder support. Historical price action for the separate_debt_short_eq metric is recorded at 0.00. The business relies on outsourcing production and testing, allowing the team to remain agile without incurring capital expenditures.

This ratio measures the proportion of short-term liabilities within the equity structure, allowing for an assessment of liquidity and default risk over a one-year horizon. Analyzing the current level of short-term debt-to-equity is critically important for Iterum Therapeutics plc (ITRM), as the lack of revenue prior to FDA approval leaves the company dependent on external financing to launch its antibiotic ecosystem.